文献速递中医内科中药与中成药合理使用

生白口服液经PPBP改善化疗后白细胞减少的多组学机制

System pharmacology reveals the mechanism of action of Shengbai Oral Liquid alleviates chemotherapy-induced leukopenia by interfering the pro-platelet basic protein: Integrated network study of multi-omics.
PubMed 文献 · J Ethnopharmacol · 2025-08-11

该研究以环磷酰胺诱导的小鼠白细胞减少模型为对象,结合转录组、蛋白组、代谢组与网络药理学预测生白口服液的作用靶点。结果显示生白口服液可升高外周血白细胞、增加骨髓造血干祖细胞数量并提升血清造血因子水平,PPBP为其关键相关靶点。

要点

  • 生白口服液可升高化疗小鼠外周血白细胞计数并增强骨髓细胞增殖活性。
  • 其作用与增加骨髓HSCs、HPCs、ST-HSCs及MPPs数量、降低脾指数相关。
  • PPBP、ALOXE3、CCR1为多组学与网络药理学提示的关键靶点。

核心结论

  • 生白口服液可显著改善环磷酰胺诱导的小鼠白细胞减少,机制与提升骨髓造血干祖细胞数量及血清造血因子水平、恢复PPBP表达相关。

研究设计与样本

  • 采用环磷酰胺建立小鼠白细胞减少模型,生白口服液口服给药18天。
  • 开展转录组学、蛋白组学和代谢组学研究,并整合多组学与网络药理学预测靶点与通路。
  • 最后通过实验验证分子机制并识别潜在治疗靶点。

主要发现

  • 生白口服液显著升高白细胞减少小鼠外周血白细胞计数,并显著增加骨髓细胞数量与增殖活性。
  • 流式细胞术显示生白口服液增加骨髓中HSCs、HPCs、ST-HSCs和MPPs数量,并降低脾指数、逆转脾内HSPCs代偿性增加。
  • 转录组提示涉及脂质代谢与免疫调节,蛋白组提示白细胞迁移与趋化相关通路,代谢组突出花生四烯酸与氨基酸代谢。
  • 多组学与网络药理学提示PPBP、ALOXE3、CCR1为关键靶点。
  • 实验证实生白口服液升高CXCL12、TGF-β1、IL-34、IL-5和GM-CSF水平,并逆转骨髓细胞PPBP表达下降、恢复血清PPBP水平。

临床怎么用

  • 对化疗后白细胞减少患者,生白口服液可作为提升白细胞与骨髓造血功能的候选中成药方案。
  • PPBP可作为评估生白口服液疗效或探索化疗后白细胞减少机制的潜在生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Epimedium brevicornu Maxim., when used alone or as the principal component in traditional Chinese medicine (TCM) formulas, has the function of restoring internal "organs" and relieving fatigue. Shengbai Oral Liquid (SBOL), a TCM formula primarily composed of Epimedium brevicornu Maxim., has demonstrated clinical efficacy in managing chemotherapy- or radiotherapy-induced leukocytopenia. Nevertheless, its therapeutic mechanisms remain unclear. AIM OF THE STUDY: Elucidate the mechanism of SBOL in treating chemotherapy-induced leukopenia. METHODS: A leukopenia model in mice was established using cyclophosphamide (CTX). Transcriptomic, proteomic, and metabolomic studies were performed to investigate mechanistic effects of SBOL at the genetic, protein, and metabolic levels. A comprehensive approach integrating multi-omics and network pharmacology was then employed to predict potential targets and pathways underlying the effects of SBOL. Finally, experiments were performed to validate the underlying molecular mechanisms and identify potential therapeutic targets. RESULTS: SBOL (oral treatment for 18 days) significantly increased the white blood cell (WBC) count in the peripheral blood of mice with leukopenia. Additionally, SBOL can significantly increase the quantity and proliferative activity of bone marrow cells (BMCs). Further flow cytometry analysis showed that SBOL can increase the number of hematopoietic stem and progenitor cells (HSPCs) in BMCs. Specifically, it increased the populations of hematopoietic stem cells (HSCs), hematopoietic progenitor cells (HPCs), short term hematopoietic stem cells (ST-HSCs), and multipotent progenitor cells (MPPs) within the HSPCs. What is more, SBOL can also reduce spleen index and reverse the compensatory increase of HSPCs in the spleen. Transcriptomic analysis indicated SBOL is involved in lipid metabolism and immune regulation, while proteomic analysis identified pathways related to leukocyte migration and chemotaxis. Metabolomic analysis highlighted arachidonic acid and amino acid metabolism. Multi-omics and network pharmacology studies have suggested that Pro-Platelet Basic Protein (PPBP), ALOXE3, and CCR1 are key targets. Experiments confirmed that SBOL significantly elevated levels of hematopoietic factors, including CXCL12, TGF-β1, IL-34, IL-5, and GM-CSF. Additionally, SBOL reversed the decreased expression of PPBP in BMCs and restored serum PPBP levels in these mice with leukopenia. CONCLUSION: SBOL significantly alleviates leukopenia induced by chemotherapy. It increases the bone marrow HSPCs counts and elevates serum hematopoietic factors levels in chemotherapy-treated mice, thereby restoring hematopoietic function and boosting WBCs counts. PPBP is closely related to the treatment of chemotherapy induced leukopenia by SBOL.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Wu S, Wu R, Ma S, et al. System pharmacology reveals the mechanism of action of Shengbai Oral Liquid alleviates chemotherapy-induced leukopenia by interfering the pro-platelet basic protein: Integrated network study of multi-omics. J Ethnopharmacol. 2025. PMID: 40769436. doi:10.1016/j.jep.2025.120351

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。